The difference between playing the stock market and the horses is that one of the horses must win.” - Joey Adams ...

Argenica Therapeutics (ASX:AGN), has announced fabulous results from a pilot study assessing the efficacy of lead drug ...

Good afternoon, everyone, and welcome to the Panbela Therapeutics first-quarter 2024 earnings call. (Operator Instructions) Please note, this conference is being recorded. I will now turn the ...

Roche said the U.S. Food and Drug Administration (FDA) gave priority review to Tecentriq mixed with the chemotherapy Abraxane for initial treatment of people with metastatic triple-negative breast ...

and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company ...

Given the delay in some key launches like generic versions of Advair (asthma) and Abraxane (cancer), which have been pushed ...

Market OverviewGlobal Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 21.7 Bn in 2023, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.The ...

The complexity of the pharmaceutical supply chain makes it difficult to identify the reasons for drug product shortages. UUDIS has been unable to identify a reason for one fourth of the shortages ...

What Types of Drugs Are in Short Supply and Why?